FigureĀ 3.
Survival curves for pediatric patients with KMT2A-rearranged AML with and without specific, recurring ACAs. Kaplan-Meier estimates of EFS of patients with and without (A) add (12p), (B) del(9q), (C) monosomy 10, (D) trisomy 1, (E) trisomy 4, (F) trisomy 6, (G) trisomy 8, (H) trisomy 12, (I) trisomy 16, (J) trisomy 17, and (K) trisomy X. Patients with specific ACAs are compared with patients with other ACAs.

Survival curves for pediatric patients with KMT2A-rearranged AML with and without specific, recurring ACAs. Kaplan-Meier estimates of EFS of patients with and without (A) add (12p), (B) del(9q), (C) monosomy 10, (D) trisomy 1, (E) trisomy 4, (F) trisomy 6, (G) trisomy 8, (H) trisomy 12, (I) trisomy 16, (J) trisomy 17, and (K) trisomy X. Patients with specific ACAs are compared with patients with other ACAs.

Close Modal

or Create an Account

Close Modal
Close Modal